

# WO200153312 Comparison

ID AAM39781 standard; Protein; 772 AA.  
XX  
AC AAM39781;  
XX  
DT 22-OCT-2001 (first entry)  
XX  
DE Human polypeptide SEQ ID NO 2926.  
XX  
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;  
KW peripheral nervous system; neuropathy; central nervous system; CNS;  
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;  
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;  
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;  
KW leukaemia.  
XX  
OS Homo sapiens.  
XX  
PN WO200153312-A1.  
XX  
PD 26-JUL-2001.  
XX  
PF 26-DEC-2000; 2000WO-US34263.  
XX  
PR 21-JAN-2000; 2000US-0488725.  
PR 25-APR-2000; 2000US-0552317.  
PR 09-JUL-2000; 2000US-0598042.  
PR 19-JUL-2000; 2000US-0620312.  
PR 03-AUG-2000; 2000US-0653450.  
PR 14-SEP-2000; 2000US-0662191.  
PR 19-OCT-2000; 2000US-0693036.  
PR 29-NOV-2000; 2000US-0727344.  
XX  
PA (HYSE-) HYSEQ INC.  
XX  
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;  
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;  
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;  
XX  
DR WPI; 2001-442253/47.  
DR N-PSDB; AAI58937.  
XX  
PT Novel nucleic acids and polypeptides, useful for treating disorders  
PT such as central nervous system injuries -  
XX  
PS Example 4; SEQ ID NO 2926; 10078pp; English.  
XX  
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and  
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,  
CC immunosuppressant and cytostatic activity. The polynucleotides are useful  
CC in gene therapy. A composition containing a polypeptide or polynucleotide  
CC of the invention may be used to treat diseases of the peripheral nervous  
CC system, such as peripheral nervous injuries, peripheral neuropathy and  
CC localised neuropathies and central nervous system diseases, such as  
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic  
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the  
CC utilisation of the activities such as: Immune system suppression,  
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic

CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,  
 CC assays for receptor activity, arthritis and inflammation, leukaemias and  
 CC C.N.S disorders.  
 CC Note: The sequence data for this patent did not form part of the printed  
 CC specification.  
 XX  
 SQ Sequence 772 AA;

Query Match 100.0%; Score 4037; DB 22; Length 772;  
 Best Local Similarity 100.0%; Pred. No. 0;  
 Matches 772; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	MRLSSLLALLRPALPLILGLSLGCSLSLLRVSWIQEGEDPCVEAVGERGGPQNPDSSRAR	60
Db	1	mrlssllallrpalplilglslgcsllrvswiqegedpcveavgerggpqnpsrar	60
Qy	61	LDQSDDEDFKPRIVPYRDPNKPYPKVLRTYIQTTELGSRELLVAVLTSRATLSTLAVAV	120
Db	61	ldqsdedfkprivpyrddpnkpykvlrtryiqtelgsrerllvavltsratlstlavav	120
Qy	121	NRTVAHHFPRLLYFTGQRGARAPAGMQVVSHGDERPAWLMSETLRHLHTHFGADYDWFFI	180
Db	121	nrtvahhfprllyftgqrgarapagmqvvshgderpawlmsetlrhlhthfgadydwffi	180
Qy	181	MQDDTYVQAPRLAALAGHLSINQDLYLGRAEEFIGAGEQARYCHGGFGYLLSRSLRLR	240
Db	181	mqddtyvqaprlaalaghlsinqdylgraeefigageqarychggfgyllsrslrlr	240
Qy	241	PHLDGCRGDILSARPDEWLGRCLIDSLGVCVSHQGGQYRSFELAKNRDPEKEGSSAFL	300
Db	241	phldgcrgdilsarpdewlgrclidslgvcvshqggqyrsfelaknrdpekegssafll	300
Qy	301	SAFAVHPVSEGLMYRLHKRFSALELERAYSEIEQLQAQIRNLTVLTPEGEAGLSWPVGL	360
Db	301	safavhvpsegtlmyrlhkrfsalelerayseieqlqaqirnlvtltpgeaglswpvgl	360
Qy	361	PAPFTPHSRFEVLGWDYFTEQHTFSCADGAPKCPLOGASRADVGDALETALEQLNRRYQP	420
Db	361	papftphsrfevlgwdyfteqhtfscadgapkcplqgasradvgdaletaleqlnrryqp	420
Qy	421	RLRFQKQRLNGYRRFDPARGMEYTLDDLLECVTQRGHRRALARRVSLRPLSRVEILPM	480
Db	421	rlrfqkqrllngyrrfdpargmeytlddllecvtqrghrralarrvslrplsrveilpm	480
Qy	481	PYVTEATRVQLVLPPLVAEAAAAPAFLEAFAANVLEPREHALLTLLLVYGPREGGRGAPD	540
Db	481	pyvteatrqlvlpplvaeaaaapafleafaanvleprehalltlllvygppreggrgapd	540
Qy	541	PFLGVKAAAELERRYPGTRLAWLAVRAEAPSQVRLMDVVSKKHPVDTLFFLTWTRPG	600
Db	541	pflgvkaaaelerrypgtrlawlavraeapsqvrldvsvskkhpvdtlffltwtrpg	600
Qy	601	PEVLNRCRMNAISGWQAFFPVHFQEFNPALSPQRSPPGPPGAGPDPPSPPGADPSRGAPI	660
Db	601	pevlnrcrmnaisgwqaffpvhfqefnpalspqrspgppgagpdppspgpadpsrgapi	660

Qy 661 GGRFDRQASAEGCFYNADYLAARARLAGELAGQEEEEALEGLEVMDVFLRFSGLHLFRAV 720  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Db 661 ggrfdrqasaegcfynadylaararlagelagqeeeealeglevmdvflrfsglhlfrav 720  
 Qy 721 EPGLVQKFSLRDCSPRLSEELYHRCRLSNLEGLGGRAQLAMALFEQE QANST 772  
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 Db 721 epglvqkfslrdcsprlseelyhrcrlsnleglggraqlamalfeqeqanst 772

RESULT 2

AAB80269

ID AAB80269 standard; Protein; 772 AA.

XX

AC AAB80269;

XX

DT 24-APR-2001 (first entry)

XX

DE Human PRO339 protein.

XX

KW Human; PRO; dermatological; antipsoriatic; cytostatic; antiinflammatory;  
 KW antiparkinsonian nootropic; neuroprotective; vulnerary; cardiant;  
 KW antiangiogenic; vasotropic; antiasthmatic; antirheumatic; cancer;  
 KW antiarthritic; antiinfertility; antidiabetic; antiviral; diabetes;  
 KW ophthalmological; gene therapy; skin disease; gastrointestinal disorder;  
 KW ischaemia; inflammation.

XX

OS Homo sapiens.

XX

PN WO200104311-A1.

XX

PD 18-JAN-2001.

XX

PF 22-FEB-2000; 2000WO-US04414.

XX

PR 07-JUL-1999; 99US-0143048.

PR 26-JUL-1999; 99US-0145698.

PR 28-JUL-1999; 99US-0146222.

PR 08-SEP-1999; 99WO-US20594.

PR 13-SEP-1999; 99WO-US20944.

PR 15-SEP-1999; 99WO-US21090.

PR 15-SEP-1999; 99WO-US21547.

PR 05-OCT-1999; 99WO-US23089.

PR 29-NOV-1999; 99WO-US28214.

PR 30-NOV-1999; 99WO-US28313.

PR 16-DEC-1999; 99WO-US30095.

PR 20-DEC-1999; 99WO-US30911.

PR 20-DEC-1999; 99WO-US30999.

PR 05-JAN-2000; 99WO-US00219.

XX

PA (GETH ) GENENTECH INC.

XX

PI Ashkenazi AJ, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ, Kljavin IJ;  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;

XX

ID AAI58937 standard; cDNA; 2710 BP.  
AC AAI58937;  
DT 22-OCT-2001 (first entry)  
DE Human polynucleotide SEQ ID NO 1140.  
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;  
KW peripheral nervous system; neuropathy; central nervous system; CNS;  
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;  
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;  
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;  
KW leukaemia; ss.  
OS Homo sapiens.  
XX  
PN WO200153312-A1.  
XX  
PD 26-JUL-2001.  
XX  
PF 26-DEC-2000; 2000WO-US34263.  
XX  
PR 21-JAN-2000; 2000US-0488725.  
PR 25-APR-2000; 2000US-0552317.  
PR 09-JUL-2000; 2000US-0598042.  
PR 19-JUL-2000; 2000US-0620312.  
PR 03-AUG-2000; 2000US-0653450.  
PR 14-SEP-2000; 2000US-0662191.  
PR 19-OCT-2000; 2000US-0693036.  
PR 29-NOV-2000; 2000US-0727344.  
XX  
PA (HYSE-) HYSEQ INC.  
XX  
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;  
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;  
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;  
XX  
DR WPI; 2001-442253/47.  
DR P-PSDB; AAM39781.  
XX  
PT Novel nucleic acids and polypeptides, useful for treating disorders  
PT such as central nervous system injuries -  
XX  
FS Claim 1; SEQ ID NO 1140; 10078pp; English.  
XX  
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and  
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,  
CC immunosuppressant and cytostatic activity. The polynucleotides are useful  
CC in gene therapy. A composition containing a polypeptide or polynucleotide  
CC of the invention may be used to treat diseases of the peripheral nervous  
CC system, such as peripheral nervous injuries, peripheral neuropathy and  
CC localised neuropathies and central nervous system diseases, such as  
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic  
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the  
CC utilisation of the activities such as: Immune system suppression,  
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic  
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,  
CC assays for receptor activity, arthritis and inflammation, leukaemias and  
CC C.N.S disorders.  
CC Note: The sequence data for this patent did not form part of the printed  
CC specification.  
XX  
SQ Sequence 2710 BP; 506 A; 821 C; 824 G; 559 T; 0 other;

Query Match 96.5%; Score 2692; DB 22; Length 2710;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 2692; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 98 gggggtagttccgacaccttcacagttgaagagcaggcagaaggagttgtgaagacagg 157

Db 7 |||||tagttccgacaccttcacagttgaagagcaggcagaaggagtgtgaagacagg 66  
 Qy 158 acaatcttcttggggatgctggtcctggaagccagcgggcttctctgtcttggcctc 217  
 Db 67 acaatcttcttggggatgctggtcctggaagccagcgggcttctctgtcttggcctc 126  
 Qy 218 attgacccaggttctctggttaaaactgaaagcctactactggcctggtgcccataat 277  
 Db 127 attgacccaggttctctggttaaaactgaaagcctactactggcctggtgcccataat 186  
 Qy 278 ccattgatccttgaggctgtgccccctggggcaccacctggcagggcctaccaccatgcg 337  
 Db 187 ccattgatccttgaggctgtgccccctggggcaccacctggcagggcctaccaccatgcg 246  
 Qy 338 actgagctccctgttggtctgctgccccagcgttccccctcatcttagggtgtctct 397  
 Db 247 actgagctccctgttggtctgctgccccagcgttccccctcatcttagggtgtctct 306  
 Qy 398 ggggtgcagcctgagcctcctgcgggtttcctggatccaggggaggagagaagatccctg 457  
 Db 307 ggggtgcagcctgagcctcctgcgggtttcctggatccaggggaggagagaagatccctg 366  
 Qy 458 tgtcagagctgtaggggagcaggaggccacagaatccagattcgagagctcggctaga 517  
 Db 367 tgtcagagctgtaggggagcaggaggccacagaatccagattcgagagctcggctaga 426  
 Qy 518 ccaaagtgatgaagacttcaaaccccggtatgtccctactacagggaacccaacaagcc 577  
 Db 427 ccaaagtgatgaagacttcaaaccccggtatgtccctactacagggaacccaacaagcc 486  
 Qy 578 ctacaagaagggtgctcaggactcgggtacatccagacagagctgggctcccgtagcggtt 637  
 Db 487 ctacaagaagggtgctcaggactcgggtacatccagacagagctgggctcccgtagcggtt 546  
 Qy 638 gctggtggctgtcctgacctcccgagctacactgtccactttggccgtggctgtgaaccg 697  
 Db 547 gctggtggctgtcctgacctcccgagctacactgtccactttggccgtggctgtgaaccg 606  
 Qy 698 tacggtggcccatcacttccctcggttactctacttcaactgggcagcggggggcccgggc 757  
 Db 607 tacggtggcccatcacttccctcggttactctacttcaactgggcagcggggggcccgggc 666  
 Qy 758 tccagcagggtatgcaggtggtgtctcatggggatgagcggcccgctggctcatgtcaga 817  
 Db 667 tccagcagggtatgcaggtggtgtctcatggggatgagcggcccgctggctcatgtcaga 726  
 Qy 818 gaccctgcgccaccttcacacacactttggggccgactacgactggttcttcatcatgca 877  
 Db 727 gaccctgcgccaccttcacacacactttggggccgactacgactggttcttcatcatgca 786  
 Qy 878 ggatgacacatatgtgcaggcccccccgctggcagcccttctggccacctcagcatcaa 937  
 Db 787 ggatgacacatatgtgcaggcccccccgctggcagcccttctggccacctcagcatcaa 846  
 Qy 938 ccaagacctgtacttaggccgggcagaggagtccattggcgaggcgagcaggcccggtta 997  
 Db 847 ccaagacctgtacttaggccgggcagaggagtccattggcgaggcgagcaggcccggtta 906  
 Qy 998 ctgtcatgggggctttggctacctgtgtgacggagtctcctgctctgctgcccacaca 1057  
 Db 907 ctgtcatgggggctttggctacctgtgtgacggagtctcctgctctgctgcccacaca 966  
 Qy 1058 tctggatggctgcgaggagacattctcagtgcctcctgacgagtggttggacgctg 1117  
 Db 967 tctggatggctgcgaggagacattctcagtgcctcctgacgagtggttggacgctg 1026

QY 1118 cctcattgactctctgggctggctgtgtctcacagcaccaggggcagcagtatcgctc 1177  
 |||  
 Db 1027 cctcattgactctctgggctggctgtgtctcacagcaccaggggcagcagtatcgctc 1086  
 |||

QY 1178 atttgaactggccaaaaatagggacctgagaaggaaggagctcggctttcctgagtg 1237  
 |||  
 Db 1087 atttgaactggccaaaaatagggacctgagaaggaaggagctcggctttcctgagtg 1146  
 |||

QY 1238 ctctgccgtgcaccctgtctccgaagggtacctcatgtaccggctccacaaacgcttcag 1297  
 |||  
 Db 1147 ctctgccgtgcaccctgtctccgaagggtacctcatgtaccggctccacaaacgcttcag 1206  
 |||

QY 1298 cgctctggagttggagcgggttacagtgaatagaacaactgcaggtcagatccggaa 1357  
 |||  
 Db 1207 cgctctggagttggagcgggttacagtgaatagaacaactgcaggtcagatccggaa 1266  
 |||

QY 1358 cctgaccgtgctgacccccgaaggggaggcagggctgagctggcccgctgggctccctgc 1417  
 |||  
 Db 1267 cctgaccgtgctgacccccgaaggggaggcagggctgagctggcccgctgggctccctgc 1326  
 |||

QY 1418 tcctttcacaccacactctcgtttgaggtgctgggctgggactacttcacagagcagca 1477  
 |||  
 Db 1327 tcctttcacaccacactctcgtttgaggtgctgggctgggactacttcacagagcagca 1386  
 |||

QY 1478 caccttctcctgtgcagatggggtcccaagtgccactacaggggcttagcagggcgga 1537  
 |||  
 Db 1387 caccttctcctgtgcagatggggtcccaagtgccactacaggggcttagcagggcgga 1446  
 |||

QY 1538 cgtgggtgatgcttggagactgcctggagcagctcaatcggcgtatcagccccgcct 1597  
 |||  
 Db 1447 cgtgggtgatgcttggagactgcctggagcagctcaatcggcgtatcagccccgcct 1506  
 |||

QY 1598 gcgcttcagaagcagcagctgctcaacggctatcggcgttcgaccagcaggggcat 1657  
 |||  
 Db 1507 gcgcttcagaagcagcagctgctcaacggctatcggcgttcgaccagcaggggcat 1566  
 |||

QY 1658 ggagtacacctggacctgctgttggaaatgtgtgacacagcgtgggcaccggcgggccct 1717  
 |||  
 Db 1567 ggagtacacctggacctgctgttggaaatgtgtgacacagcgtgggcaccggcgggccct 1626  
 |||

QY 1718 ggctcgcagggtcagcctgctgcggccactgagcgggtggaaatcctacctatgcccta 1777  
 |||  
 Db 1627 ggctcgcagggtcagcctgctgcggccactgagcgggtggaaatcctacctatgcccta 1686  
 |||

QY 1778 tgtcactgagggcaccagtgctgagctggtgctgccactcctggtggctgaagctgctgc 1837  
 |||  
 Db 1687 tgtcactgagggcaccagtgctgagctggtgctgccactcctggtggctgaagctgctgc 1746  
 |||

QY 1838 agccccggctttcctcgaggcgttgcagccaatgtcctggagccacgagaacatgcatt 1897  
 |||  
 Db 1747 agccccggctttcctcgaggcgttgcagccaatgtcctggagccacgagaacatgcatt 1806  
 |||

QY 1898 gctcaccctgttgcgtgtctacgggccacgagaaggtggcggtggagctccagaccatt 1957  
 |||  
 Db 1807 gctcaccctgttgcgtgtctacgggccacgagaaggtggcggtggagctccagaccatt 1866  
 |||

QY 1958 tcttgggggtgaaggctgcagcagcggagttagagcgacgggtacctgggacgaggtggc 2017  
 |||  
 Db 1867 tcttgggggtgaaggctgcagcagcggagttagagcgacgggtacctgggacgaggtggc 1926  
 |||

QY 2018 ctggctcgtgtgcgagcagaggcccttcccagggtgcgactcatggacgtggtctcgaa 2077  
 |||  
 Db 1927 ctggctcgtgtgcgagcagaggcccttcccagggtgcgactcatggacgtggtctcgaa 1986  
 |||

QY 2078 gaagcaccctgtggacactctcttcttcttaccaccgtgtggacaaggcctgggcccga 2137

Db	1987	gaagcaccctgtggacactctcttcttcttaccacogtgtggacaaggcctgggcccga	2046
Qy	2138	agtcctcaaccgctgtcgcatgaatgccatctctggetggcaggccttctttccagtcca	2197
Db	2047	agtcctcaaccgctgtcgcatgaatgccatctctggetggcaggccttctttccagtcca	2106
Qy	2198	tttccaggagtccaatcctgcctgtcaccacagagatcacccccaggggccccgggggc	2257
Db	2107	tttccaggagtccaatcctgcctgtcaccacagagatcacccccaggggccccgggggc	2166
Qy	2258	tggcctgacccccctccctcctggtgctgacccctcccggggggctcctataggggg	2317
Db	2167	tggcctgacccccctccctcctggtgctgacccctcccggggggctcctataggggg	2226
Qy	2318	gagatttgaccggcaggcttctgaggagggtgcttctacaacgctgactacctggcggc	2377
Db	2227	gagatttgaccggcaggcttctgaggagggtgcttctacaacgctgactacctggcggc	2286
Qy	2378	ccgagccccggtggcagggtgaactggcaggccagggaagaggaggaagccctggaggggct	2437
Db	2287	ccgagccccggtggcagggtgaactggcaggccagggaagaggaggaagccctggaggggct	2346
Qy	2438	ggagggtgatggatgttttctccgggttctcagggtccacctcttccggggccgtagagcc	2497
Db	2347	ggagggtgatggatgttttctccgggttctcagggtccacctcttccggggccgtagagcc	2406
Qy	2498	agggtggtgcagaagtcttccctgcgagactgcagcccacggctcagtgaagaactcta	2557
Db	2407	agggtggtgcagaagtcttccctgcgagactgcagcccacggctcagtgaagaactcta	2466
Qy	2558	ccaccgctgccgcctcagcaacctggaggggctagggggccgtgccagctggctatggc	2617
Db	2467	ccaccgctgccgcctcagcaacctggaggggctagggggccgtgccagctggctatggc	2526
Qy	2618	tctctttgagcaggagcaggccaatagcaettagccgcctggggggcctaaccctatta	2677
Db	2527	tctctttgagcaggagcaggccaatagcaettagccgcctggggggcctaaccctatta	2586
Qy	2678	cctttcctttgtctgcctcagccccaggaagggcaaggcaagatgggtggacagatagaga	2737
Db	2587	cctttcctttgtctgcctcagccccaggaagggcaaggcaagatgggtggacagatagaga	2646
Qy	2738	attgttgctgtattttttaaataatgaaaatgttattaaacatgtcttctgcc	2789
Db	2647	attgttgctgtattttttaaataatgaaaatgttattaaacatgtcttctgcc	2698